Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis

Dengfeng Li, Hong Wang, Ye Ding, Ziwei Zhang, Zhi Zheng, Jiabin Dong, Hyejin Kim, Xiaojing Meng, Qianjun Zhou, Jia Zhou, Lin Fang, Qiang Shen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Metastasis is a major cause of breast cancer-associated mortality. Natural products extracted from herbs provide rich bioactive compounds with anticancer efficacy but may have limited or moderate potency and considerable toxicity. We developed a novel aziridonin, YD0514, by aziridinating oridonin, a natural product of the medicinal herb Rabdosia rubescens. In this study, we found that YD0514 significantly inhibited proliferation, motility, and adhesion of metastatic breast cancer cell lines MDA-MB-231, GI101, GILM2, and GILM3. YD0514 also decreased the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), focal adhesion kinase (FAK), and integrin family members. Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo. Lastly, we showed that YD0514's anti-metastatic effect on highly aggressive breast cancer is mediated via regulating the NRF-2/RHOA/ROCK signaling pathway. These results demonstrate that YD0514, the first active analog based on an oridonin D-ring modification, has the potential to be developed as an anti-metastasis therapy for patients with metastatic cancers.

Original languageEnglish (US)
Pages (from-to)97-108
Number of pages12
JournalCancer Letters
Volume424
DOIs
StatePublished - Jun 28 2018

Fingerprint

Lung Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Biological Products
Isodon
Focal Adhesion Protein-Tyrosine Kinases
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Medicinal Plants
Heterografts
Integrins
Neoplasms
Cell Line
Lung
Mortality
Growth
Proteins
oridonin
Therapeutics

Keywords

  • Aziridonin
  • Breast cancer
  • Metastasis
  • NRF-2/RHOA/ROCK pathway
  • Oridonin
  • YD0514

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis. / Li, Dengfeng; Wang, Hong; Ding, Ye; Zhang, Ziwei; Zheng, Zhi; Dong, Jiabin; Kim, Hyejin; Meng, Xiaojing; Zhou, Qianjun; Zhou, Jia; Fang, Lin; Shen, Qiang.

In: Cancer Letters, Vol. 424, 28.06.2018, p. 97-108.

Research output: Contribution to journalArticle

Li, Dengfeng ; Wang, Hong ; Ding, Ye ; Zhang, Ziwei ; Zheng, Zhi ; Dong, Jiabin ; Kim, Hyejin ; Meng, Xiaojing ; Zhou, Qianjun ; Zhou, Jia ; Fang, Lin ; Shen, Qiang. / Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis. In: Cancer Letters. 2018 ; Vol. 424. pp. 97-108.
@article{15e1870aed744b8c96b1beb50a360850,
title = "Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis",
abstract = "Metastasis is a major cause of breast cancer-associated mortality. Natural products extracted from herbs provide rich bioactive compounds with anticancer efficacy but may have limited or moderate potency and considerable toxicity. We developed a novel aziridonin, YD0514, by aziridinating oridonin, a natural product of the medicinal herb Rabdosia rubescens. In this study, we found that YD0514 significantly inhibited proliferation, motility, and adhesion of metastatic breast cancer cell lines MDA-MB-231, GI101, GILM2, and GILM3. YD0514 also decreased the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), focal adhesion kinase (FAK), and integrin family members. Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo. Lastly, we showed that YD0514's anti-metastatic effect on highly aggressive breast cancer is mediated via regulating the NRF-2/RHOA/ROCK signaling pathway. These results demonstrate that YD0514, the first active analog based on an oridonin D-ring modification, has the potential to be developed as an anti-metastasis therapy for patients with metastatic cancers.",
keywords = "Aziridonin, Breast cancer, Metastasis, NRF-2/RHOA/ROCK pathway, Oridonin, YD0514",
author = "Dengfeng Li and Hong Wang and Ye Ding and Ziwei Zhang and Zhi Zheng and Jiabin Dong and Hyejin Kim and Xiaojing Meng and Qianjun Zhou and Jia Zhou and Lin Fang and Qiang Shen",
year = "2018",
month = "6",
day = "28",
doi = "10.1016/j.canlet.2018.03.029",
language = "English (US)",
volume = "424",
pages = "97--108",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis

AU - Li, Dengfeng

AU - Wang, Hong

AU - Ding, Ye

AU - Zhang, Ziwei

AU - Zheng, Zhi

AU - Dong, Jiabin

AU - Kim, Hyejin

AU - Meng, Xiaojing

AU - Zhou, Qianjun

AU - Zhou, Jia

AU - Fang, Lin

AU - Shen, Qiang

PY - 2018/6/28

Y1 - 2018/6/28

N2 - Metastasis is a major cause of breast cancer-associated mortality. Natural products extracted from herbs provide rich bioactive compounds with anticancer efficacy but may have limited or moderate potency and considerable toxicity. We developed a novel aziridonin, YD0514, by aziridinating oridonin, a natural product of the medicinal herb Rabdosia rubescens. In this study, we found that YD0514 significantly inhibited proliferation, motility, and adhesion of metastatic breast cancer cell lines MDA-MB-231, GI101, GILM2, and GILM3. YD0514 also decreased the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), focal adhesion kinase (FAK), and integrin family members. Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo. Lastly, we showed that YD0514's anti-metastatic effect on highly aggressive breast cancer is mediated via regulating the NRF-2/RHOA/ROCK signaling pathway. These results demonstrate that YD0514, the first active analog based on an oridonin D-ring modification, has the potential to be developed as an anti-metastasis therapy for patients with metastatic cancers.

AB - Metastasis is a major cause of breast cancer-associated mortality. Natural products extracted from herbs provide rich bioactive compounds with anticancer efficacy but may have limited or moderate potency and considerable toxicity. We developed a novel aziridonin, YD0514, by aziridinating oridonin, a natural product of the medicinal herb Rabdosia rubescens. In this study, we found that YD0514 significantly inhibited proliferation, motility, and adhesion of metastatic breast cancer cell lines MDA-MB-231, GI101, GILM2, and GILM3. YD0514 also decreased the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), focal adhesion kinase (FAK), and integrin family members. Importantly, YD0514 suppressed the growth of metastatic breast cancer xenograft tumors and significantly inhibited lung metastasis in vivo. Lastly, we showed that YD0514's anti-metastatic effect on highly aggressive breast cancer is mediated via regulating the NRF-2/RHOA/ROCK signaling pathway. These results demonstrate that YD0514, the first active analog based on an oridonin D-ring modification, has the potential to be developed as an anti-metastasis therapy for patients with metastatic cancers.

KW - Aziridonin

KW - Breast cancer

KW - Metastasis

KW - NRF-2/RHOA/ROCK pathway

KW - Oridonin

KW - YD0514

UR - http://www.scopus.com/inward/record.url?scp=85044543516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044543516&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2018.03.029

DO - 10.1016/j.canlet.2018.03.029

M3 - Article

VL - 424

SP - 97

EP - 108

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -